Damiano Patrono

Dr. Damiano Patrono


Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2022 in Journal of Hepatology
Verified
Journal Article
Closed access
ASAndrea Schlegel
Andrea Schlegel
MRMarjolein van Reeven
Marjolein van Reeven
KCKristopher Croome
Kristopher Croome
APAlessandro Parente
Alessandro Parente
ADAnnalisa Dolcet
Annalisa Dolcet
EWErin Winter
Erin Winter

27 June 2019 in Scientific Reports
Verified
Journal Article
Open access
PDF file
DPDamiano Patrono
Damiano Patrono
ASAstrid Surra
Astrid Surra
GCGiorgia Catalano
Giorgia Catalano
GRGiorgia Rizza
Giorgia Rizza
Paola BerchiallaPaola Berchialla
Paola Berchialla
RRRenato Romagnoli
Renato Romagnoli
Hypothermic oxygenated machine perfusion (HOPE) was introduced in liver transplantation (LT) to mitigate ischemia-reperfusion injury. Available clinical data mainly concern LT with donors after circulatory-determined death, whereas data on brain-dead donors (DBD) are scarce. To assess the impact of end-ischemic HOPE in DBD LT, data on primary adult LTs performed between March 2016 and June 2018 were analyzed. HOPE was used in selected cases of donor age >80 years, apparent severe graft steatosis, or ischemia time ≥10 hours. Outcomes of HOPE-treated cases were compared with those after static cold storage. Propensity score matching (1:2) and Bayesian model averaging were used to overcome selection bias. During the study period, 25 (8.5%) out of 294 grafts were treated with HOPE. After matching, HOPE was associated with a lower severe post-reperfusion syndrome (PRS) rate (4% versus 20%, p = 0.13) and stage 2–3 acute kidney injury (AKI) (16% versus 42%, p = 0.046). Furthermore, Bayesian model averaging showed lower transaminases peak and a lower early allograft dysfunction (EAD) rate after HOPE. A steeper decline in arterial graft resistance throughout perfusion was associated with lower EAD rate. HOPE determines a significant reduction of ischemia reperfusion injury in DBD LT.

5 April 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
IBIsabel M.A. Brüggenwirth
Isabel M.A. Brüggenwirth
MMMatteo Mueller
Matteo Mueller
VLVeerle A. Lantinga
Veerle A. Lantinga
SCStefania Camagni
Stefania Camagni
RCRiccardo De Carlis
Riccardo De Carlis
VMVincent E. de Meijer
Vincent E. de Meijer
A short period (1–2 h) of hypothermic oxygenated machine perfusion (HOPE) after static cold storage is safe and reduces ischemia‐reperfusion injury‐related complications after liver transplantation. Machine perfusion time is occasionally prolonged for logistical reasons, but it is unknown if prolonged HOPE is safe and compromises outcomes. We conducted a multicenter, observational cohort study of patients transplanted with a liver preserved by prolonged (≥4 h) HOPE. Postoperative biochemistry, complications, and survival were evaluated. The cohort included 93 recipients from 12 European transplant centers between 2014–2021. The most common reason to prolong HOPE was the lack of an available operating room to start the transplant procedure. Grafts underwent HOPE for a median (range) of 4:42 h (4:00–8:35 h) with a total preservation time of 10:50 h (5:50–20:50 h). Postoperative peak ALT was 675 IU/L (interquartile range 419–1378 IU/L). The incidence of postoperative complications was low, and 1‐year graft and patient survival were 94% and 88%, respectively. To conclude, good outcomes are achieved after transplantation of donor livers preserved with prolonged (median 4:42 h) HOPE, leading to a total preservation time of almost 21 h. These results suggest that simple, end‐ischemic HOPE may be utilized for safe extension of the preservation time to ease transplantation logistics.

7 September 2024 in Journal of Hepatology
Verified
Journal Article
Closed access
JEJahnina Eden
Jahnina Eden
ATAdam M. Thorne
Adam M. Thorne
SBSilke Bodewes
Silke Bodewes
DPDamiano Patrono
Damiano Patrono
DRDorotea Roggio
Dorotea Roggio
PDPhilipp Dutkowski
Philipp Dutkowski

3 July 2024 in Journal of Hepatology
Verified
Journal Article
Open access
JEJanina Eden
Janina Eden
IBIsabel M.A. Brüggenwirth
Isabel M.A. Brüggenwirth
GBGabriela Berlakovich
Gabriela Berlakovich
BBBettina M. Buchholz
Bettina M. Buchholz
FBFlorin Botea
Florin Botea
VMVincent E. de Meijer
Vincent E. de Meijer
Despite strong evidence for improved preservation of donor livers by machine perfusion, longer post-transplant follow-up data are urgently needed in an unselected patient population. We aimed to assess long-term outcomes after transplantation of hypothermic oxygenated machine perfusion (HOPE)-treated donor livers based on real-world data (i.e., IDEAL-D stage 4). In this international, multicentre, observational cohort study, we collected data from adult recipients of HOPE-treated livers transplanted between January 2012 and December 2021. Analyses were stratified by donation after brain death (DBD) and donation after circulatory death (DCD), sub-divided by their respective risk categories. The primary outcome was death-censored graft survival. Secondary outcomes included the incidence of primary non-function (PNF) and ischaemic cholangiopathy (IC). We report on 1,202 liver transplantations (64% DBD) performed at 22 European centres. For DBD, a total number of 99 benchmark (8%), 176 standard (15%), and 493 extended-criteria (41%) cases were included. For DCD, 117 transplants were classified as low risk (10%), 186 as high risk (16%), and 131 as futile (11%), with significant risk profile variations among centres. Actuarial 1-, 3-, and 5-year death-censored graft survival rates for DBD and DCD livers were 95%, 92%, and 91%, vs. 92%, 87%, and 81%, respectively (log-rank p = 0.003). Within DBD and DCD strata, death-censored graft survival was similar among risk groups (log-rank p = 0.26, p = 0.99). Graft loss due to PNF or IC was 2.3% and 0.4% (DBD), and 5% and 4.1% (DCD). This study shows excellent 5-year survival after transplantation of HOPE-treated DBD and DCD livers with low rates of graft loss due to PNF or IC, irrespective of their individual risk profile. HOPE treatment has now reached IDEAL-D stage 4, which further supports its implementation in routine clinical practice. ClinicalTrials.gov Identifier: NCT05520320. This study demonstrates the excellent long-term performance of hypothermic oxygenated machine perfusion (HOPE) treatment of donation after circulatory and donation after brain death liver grafts irrespective of their individual risk profile in a real-world setting, outside the evaluation of randomised-controlled trials. While previous studies have established safety, feasibility, and efficacy against the current standard, according to the IDEAL-D evaluation framework, HOPE treatment has now reached the final IDEAL-D stage 4, which further supports its implementation in routine clinical practice.

22 February 2022 in American Journal of Transplantation
Verified
Journal Article
Open access
PDF file
DPDamiano Patrono
Damiano Patrono
DCDavide Cussa
Davide Cussa
Veronica SciannameoVeronica Sciannameo
Veronica Sciannameo
EMElena Montanari
Elena Montanari
RPRebecca Panconesi
Rebecca Panconesi
RRRenato Romagnoli
Renato Romagnoli
Prompted by the utilization of extended criteria donors, dual hypothermic oxygenated machine perfusion (D-HOPE) was introduced in liver transplantation to improve preservation. When donors after neurological determination of death (DBD) are utilized, D-HOPE effect on graft outcomes is unclear. To assess D-HOPE value in this setting and to identify ideal scenarios for its use, data on primary adult liver transplant recipients from January 2014 to April 2021 were analyzed using inverse probability of treatment weighting, comparing outcomes of D-HOPE-treated grafts (n = 121) with those preserved by static cold storage (n = 723). End-ischemic D-HOPE was systematically applied since November 2017 based on donor and recipient characteristics, and transplant logistics. D-HOPE use was associated with a significant reduction of early allograft failure (OR: 0.24; 0.83; p = 0.024), grade ≥ 3 complications (OR: 0.57; p = 0.046), comprehensive complication index (- 7.20 points; p = 0.003) and improved patient and graft survival. These results were confirmed in the subset of elderly donors (>75-year-old). Although D-HOPE did not reduce the incidence of biliary complications, its use was associated with a reduced severity of ischemic cholangiopathy. In conclusion, D-HOPE improves postoperative outcomes and reduces early allograft loss in extended criteria DBD grafts.